Citadel Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Citadel Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5M	Buy	199,800 +59,500	+42%	+$2.44M	﹤0.01%	3179
2025 Q4	$5.67M	Buy	140,300 +84,500	+151%	+$1.95M	﹤0.01%	4093
2025 Q3	$419K	Buy	+55,800	New	+$356K	﹤0.01%	9554
2025 Q2	–	Sell	-118,700	Closed	-$328K	–	15049
2025 Q1	$328K	Sell	118,700 -78,800	-40%	-$322K	﹤0.01%	9391
2024 Q4	$1.09M	Buy	197,500 +68,100	+53%	+$461K	﹤0.01%	6821
2024 Q3	$1.08M	Buy	129,400 +65,500	+103%	+$539K	﹤0.01%	6729
2024 Q2	$435K	Buy	63,900 +56,500	+764%	+$342K	﹤0.01%	8334
2024 Q1	$48.5K	Sell	7,400 -8,300	-53%	-$54.2K	﹤0.01%	12197
2023 Q4	$102K	Sell	15,700 -3,700	-19%	-$19.6K	﹤0.01%	10917
2023 Q3	$97.6K	Buy	19,400 +200	+1%	+$1.27K	﹤0.01%	10932
2023 Q2	$168K	Buy	+19,200	New	+$224K	﹤0.01%	10154

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's TERN Position: Q1 2026 in Review

Citadel Advisors increased its Terns Pharmaceuticals (TERN) stake by 1.6% in Q1 2026, buying an estimated $2.14M and bringing the position to 3,218,810 shares worth $170M. The position accounts for 0.03% of the portfolio, ranked #520.

Citadel Advisors first reported a position in TERN in Q1 2021 and has held it in 17 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Citadel Advisors held 3,218,810 shares of Terns Pharmaceuticals worth $170M as of Q1 2026.
Citadel Advisors bought 52,168 Terns Pharmaceuticals shares in Q1 2026, an estimated $2.14M.
Terns Pharmaceuticals made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #520 holding.
Citadel Advisors first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.